Topical anti-inflammatory effect of hypocholesterolaemic drugs

被引:24
作者
Bracht, Livia [1 ]
Caparroz-Assef, Silvana Martins [1 ]
dos Santos Magon, Thiago Ferreira [1 ]
Versuti Ritter, Alessandra Mileni [1 ]
Nakamura Cuman, Roberto Kenji [1 ]
Bersani-Amado, Ciomar Aparecida [1 ]
机构
[1] Univ Maringa, Lab Inflammat, Dept Pharm & Pharmacol, BR-87020900 Maringa, Parana, Brazil
关键词
atorvastatin; croton oil ear oedema; ezetimibe; pravastatin; simvastatin; SIMVASTATIN; EZETIMIBE; CHOLESTEROL; STATINS; PHARMACOLOGY; SKIN;
D O I
10.1111/j.2042-7158.2011.01302.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives The topical anti-inflammatory effect of simvastatin, atorvastatin, pravastatin, ezetimibe and combined ezetimibe + simvastatin was investigated, using the croton oil model of ear oedema in mice. Methods Simvastatin, atorvastatin, pravastatin, ezetimibe and ezetimibe + simvastatin combination (dissolved in 20 mu l of 70% acetone) were topically applied simultaneously with croton oil (200 mu g/ear, dissolved in 20 mu l of 70% acetone) at the inner surface of each ear. Ear oedema and myeloperoxidase activity, indicative of polymorphonuclear cell migration, were assessed 6 h after inflammatory stimuli. Key findings It was found that statins can act as topical anti-inflammatories, but the pharmacological effect is dependent on statin polarity. At 0.3 mg/ear inhibition of ear oedema was 79%, 67% and 40% for simvastatin, atorvastatin and pravastatin, respectively. Simvastatin and atorvastatin also remarkably diminished myeloperoxidase activity, even at low concentrations (0.03 mg/ear). Pravastatin, the most polar statin, however, did not cause any reduction in ear oedema or myeloperoxidase activity at low doses. The order of topical anti-inflammatory activity was pravastatin < < < atorvastatin < simvastatin. Ezetimibe, another hypocholesterolaemic drug, also presented anti-inflammatory effects, inhibiting ear oedema by 64% at 0.3 mg/ear. However, when used in combination with simvastatin, no further beneficial effect was observed. Conclusions These results consistently support current evidence showing that statins can be used for treatment of dermatological disorders. Polarity of the molecule, however, is a factor that should be considered before recommending use.
引用
收藏
页码:971 / 975
页数:5
相关论文
共 17 条
[1]   A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia [J].
Bays, HE ;
Ose, L ;
Fraser, N ;
Tribble, DL ;
Quinto, K ;
Reyes, R ;
Johnson-Levonas, AO ;
Sapre, A ;
Donahue, SR .
CLINICAL THERAPEUTICS, 2004, 26 (11) :1758-1773
[2]   MEASUREMENT OF CUTANEOUS INFLAMMATION - ESTIMATION OF NEUTROPHIL CONTENT WITH AN ENZYME MARKER [J].
BRADLEY, PP ;
PRIEBAT, DA ;
CHRISTENSEN, RD ;
ROTHSTEIN, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1982, 78 (03) :206-209
[3]   Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? [J].
Christians, U ;
Jacobsen, W ;
Floren, LC .
PHARMACOLOGY & THERAPEUTICS, 1998, 80 (01) :1-34
[4]   Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein [J].
Davidson, Michael H. ;
Abate, Nicola ;
Ballantyne, Christie M. ;
Catapano, Alberico L. ;
Xu, Xia ;
Lin, Jianxin ;
Rosenberg, Elizabeth ;
Tershakovec, Andrew M. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (06) :436-446
[5]   Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview [J].
Gazi, Irene F. ;
Mikhailidis, Dimitri P. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (06) :851-866
[6]   Skin, the final frontier [J].
Hadgraft, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 224 (1-2) :1-18
[7]   Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors [J].
Hamelin, BA ;
Turgeon, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (01) :26-37
[8]   Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor [J].
Jeu, L ;
Cheng, JW .
CLINICAL THERAPEUTICS, 2003, 25 (09) :2352-2387
[9]   Pleiotropic effects of ezetimibe: Do they really exist? [J].
Kalogirou, Michalis ;
Tsimihodimos, Vasilis ;
Elisaf, Moses .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 633 (1-3) :62-70
[10]   Simvastatin as a Novel Strategy To Alleviate Periapical Lesions [J].
Lin, Sze-Kwan ;
Kok, Sang-Heng ;
Lee, Yuan-Ling ;
Hou, Kuo-Liang ;
Lin, Yi-Ting ;
Chen, Mu-Hsiung ;
Wang, Chih-Chiang ;
Hong, Chi-Yuan .
JOURNAL OF ENDODONTICS, 2009, 35 (05) :657-662